3-(difluoromethyl)piperidin-3-ol hydrochloride | 1909325-03-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3-(difluoromethyl)piperidin-3-ol hydrochloride
• 英文别名: 3-(difluoromethyl)piperidin-3-ol;hydrochloride
• CAS: 1909325-03-6
• 化学式: C₆H₁₁F₂NO*ClH
• 分子量: 187.617
• InChiKey: BPFVYAUITXWPHU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.79
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.3
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  3-(difluoromethyl)piperidin-3-ol hydrochloride 、 在 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以48.3 %的产率得到
  参考文献：
  名称：

  泛-KRAS抑制剂及其在医药上的应用

  摘要：

  本发明涉及式(I)所述化合物，其立体异构体、互变异构体、氘代物或药用盐，其制备方法，含有该化合物的药用组合物，及其作为治疗和/或预防由KRAS突变介导的疾病的药物中的应用。#imgabs0#

  公开号：

  CN117736226A

文献信息

• [EN] TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS<br/>[FR] INHIBITEURS PAN-KRAS DE TÉTRAHYDROPYRIDOPYRIMIDINE
  申请人：MIRATI THERAPEUTICS INC

  公开号：WO2022133038A1

  公开（公告）日：2022-06-23

  The present invention relates to compounds that inhibit at least one of KRas wild type, KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use therefor.

  本发明涉及抑制KRas野生型、KRas G12A、KRas G12C、KRas G12D、KRas G12R、KRas G12S、KRas G12V、KRas G13D和KRas Q61H中至少一种的化合物、包含该化合物的制药组合物以及使用方法。
• [EN] SMALL MOLECULE INHIBITORS OF KRAS MUTATED PROTEINS<br/>[FR] PETITES MOLÉCULES INHIBITRICES DE PROTÉINES À MUTATION KRAS
  申请人：[en]MERCK SHARP & DOHME LLC

  公开号：WO2023097227A1

  公开（公告）日：2023-06-01

  Compounds of Formula (I) or their pharmaceutically acceptable salts can inhibit the G12C, G12D and/or G12V mutants of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.
• [EN] QUINAZOLINE COMPOUNDS AND USE THEREOF AS INHIBTORS OF MUTANT KRAS PROTEINS<br/>[FR] COMPOSÉS QUINAZOLINE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE PROTÉINES KRAS MUTANTES
  申请人：[en]AMGEN INC.

  公开号：WO2023159087A1

  公开（公告）日：2023-08-24

  The present disclosure provides compounds useful for the inhibition of KRAS G12D, G12V, G12A, G12S or G12C. The compounds have a general Formula (I): (Formula (I)) wherein the variables of Formula (I) are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, cancer.